文献速递肝肾功能剂量调整特殊人群用药

布格替尼在健康志愿者与癌症患者中的群体药代动力学

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer.
PubMed 文献 · Clin Pharmacokinet · 2021-01-01

该分析基于5项试验中442名参与者(105名健康志愿者和337名癌症患者)的数据,采用非线性混合效应模型研究布格替尼的群体药代动力学。最终模型为三室模型并含转运室输入,白蛋白作为表观清除率的协变量。性别、年龄、种族、体重、轻中度肾损伤及肝功能指标等未显著解释表观清除率变异,提示无需基于这些协变量调整剂量。

要点

  • 布格替尼药代动力学符合三室模型,含2.35个转运室,平均转运时间0.9小时。
  • 白蛋白被纳入为表观清除率的显著协变量。
  • 性别、年龄、种族、体重、轻中度肾损伤及肝功能指标未显著影响表观清除率,无需据此调整剂量。

核心结论

  • 群体药代动力学分析支持布格替尼在美国处方信息和欧洲产品特性摘要中针对轻中度肾损伤患者的用药指导。

研究设计与样本

  • 基于5项试验的群体药代动力学分析,纳入442名参与者(105名健康志愿者和337名癌症患者),接受单次或多次口服布格替尼,采用非线性混合效应模型(NONMEM 7.3)分析。

主要发现

  • 布格替尼血药浓度最佳描述为三室模型,含转运室输入(转运室数量2.35,平均转运时间0.9小时)。
  • 最终模型将白蛋白作为表观清除率的协变量。
  • 性别、年龄、种族、体重、轻中度肾损伤、总胆红素、天冬氨酸氨基转移酶和丙氨酸氨基转移酶未显著解释表观清除率变异。

关键数值与推荐

  • 基于所考察的协变量(性别、年龄、种族、体重、轻中度肾损伤、总胆红素、AST、ALT),无需调整布格替尼剂量。

临床怎么用

  • 临床对于轻中度肾损伤患者使用布格替尼时,可参考群体药代动力学结果,无需基于性别、年龄、种族、体重或肝功能指标进行剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Brigatinib is an oral tyrosine kinase inhibitor approved in multiple countries for the treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib. We report a population pharmacokinetic model-based analysis for brigatinib. METHODS: Plasma concentration-time data were collected from 442 participants (105 healthy volunteers and 337 patients with cancer) who received single or multiple doses of oral brigatinib in one of five trials. Data were analyzed using non-linear mixed-effects modeling (NONMEM software version 7.3). RESULTS: Brigatinib plasma concentrations were best described by a three-compartment model with a transit compartment input (number of transit compartments = 2.35; mean transit time = 0.9 h). The final model included albumin as a covariate on apparent clearance. None of the additional covariates examined, including sex, age, race, body weight, mild or moderate renal impairment, total bilirubin, aspartate aminotransferase, and alanine aminotransferase, were found to meaningfully explain variability in apparent clearance, suggesting that no dose adjustment is required based on these covariates. CONCLUSIONS: Results from these population pharmacokinetic analyses informed the prescribing guidance for patients with mild or moderate renal impairment in the US Prescribing Information and the European Summary of Product Characteristics for brigatinib.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Gupta N, Wang X, Offman E, et al. Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. Clin Pharmacokinet. 2021. PMID: 32816246. doi:10.1007/s40262-020-00929-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。